Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin

• Published in: Pharmacotherapy Vol. 31; no. 10; p. 942
• Main Authors: Shin, Jaekyu, Pauly, Daniel F, Pacanowski, Michael A, Langaee, Taimour, Frye, Reginald F, Johnson, Julie A
• Format: Journal Article
• Language: English
• Published: United States 01.10.2011
• Subjects: Adult; Alleles; Atorvastatin Calcium; Clarithromycin - blood; Clarithromycin - pharmacology; Cytochrome P-450 CYP3A - genetics; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Genotype; Heptanoic Acids - administration & dosage; Heptanoic Acids - blood; Heptanoic Acids - chemistry; Heptanoic Acids - pharmacokinetics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood; Hydroxymethylglutaryl-CoA Reductase Inhibitors - chemistry; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics; Male; Prospective Studies; Pyrroles - administration & dosage; Pyrroles - blood; Pyrroles - chemistry; Pyrroles - pharmacokinetics; Young Adult

Abstract Study Objective. To assess the effects of the cytochrome P450 (CYP) 3A genotype, CYP3A5, on atorvastatin pharmacokinetics and its interaction with clarithromycin. Design. Prospective, two-phase, randomized-sequence, open-label pharmacokinetic study. Setting. Clinical research center at a te...